Global Antibody Drug Conjugates Market-Outlook 2022

Posted by aarav kumar on July 25th, 2017

Antibody Drug Conjugates are monoclonal antibodies that are attached to biologically active drugs by chemical linkers with labile bonds. They combine the unique targeting property of monoclonal antibodies with the cancer cell killing ability of cytotoxic drugs. These allow discrimination between healthy and diseased tissues. Advancements in coupling monoclonal antibodies to cytotoxic drugs permit better control of drug pharmacokinetics, and significantly improve delivery to target tissue. Potent novel anticancer drugs can now be used to target cancers, while minimizing the exposure of healthy tissue. The recent approvals of two potent ADCs ADCETRIS and Kadcyla, followed by several Antibody Drug Conjugates ADCs in pipeline highlight the potential for new therapeutic innovations in this industry.

According to the RNCOS report entitled “Global Antibody Drug Conjugates Market By Drug ADCETRIS, Kadcyla, Pipeline Analysis By Phase, Mode of Action, Linker, Technology, and Indication Outlook 2022”, the ADC market is poised to reach US$ 18.1 Billion by 2022. In this report, there is indepth market analysis of ADCETRIS and Kadcyla. The market potential of these ADCs is estimated considering that these are being tested in clinical trials for several cancer indications, besides the ones which have already been approved. The depicted ADCs are expected to show their complete market potential soon in the coming years.

Furthermore, in this report, we have structured the information regarding ADCs at various stages of clinical development that are under research or in collaboration, and those individually being developed by companies. The pipeline chapter provides in depth analysis of ADCs of companies as well as research organizations by clinical phase, indications for which they are being developed, mode of action, type of linker, drugs, and technology. Additionally, the study provides allinclusive current analysis of various ADCs in advanced as well as early stages of development. Moreover, our report places an emphasis on the major drivers and challenges, latest trends and developments, as well as strategic collaborations that can impact industry’s growth.

In the end, the report enlists some of the key players in the ADC market including inshort business overview of each player along with their product and pipeline portfolios, recent developments, and comparative analysis of their strengths and weaknesses. Conclusively, the report will prove to be a complete and comprehensive source of knowledge and analysis for clients and potential investors or debut makers in this industry.

Download Free Report Sample @

Table Of Content-

1. Analyst View

2. Research Methodology

3. Antibody Drug Conjugate ADC An Introduction

4. ADC Market Outlook to 2022

5. ADC Pipeline Analysis

6. Drivers and Challenges

7. Major Potential ADCs in Pipeline

8. Trends and Developments

9. Strategic Collaborations in the ADC Industry

10. Competitive Assessment

For More Details Visit @

Contact Us-
New York City Zone 01,
United States,
Int'l: (+1) 646 781 7170,
UK(Toll free): +44 800 088 5734,
help@24marketreports.com

About the Author

aarav kumar
Joined: July 17th, 2017
Articles Posted: 91